Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House, Senate Differ In Treating FDA China Syndrome

This article was originally published in The Tan Sheet

Executive Summary

Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.

You may also be interested in...



Congress Instructs FDA On Nanotech Work, But Mum On Regulations

The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”

Congress Instructs FDA On Nanotech Work, But Mum On Regulations

The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”

Congress Instructs FDA On Nanotech Work, But Mute On Funding

Newly passed user-fee legislation includes a provision directing FDA to intensify its research and policy development regarding nanotechnology and its use in consumer products. How such efforts are to be funded remains a question.

Related Content

Topics

UsernamePublicRestriction

Register

PS105844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel